Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P N Lara

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 13, 2001
Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approachD R Gandara, P N Lara, D H Lau, et al.
The American Journal of Medicine|January 7, 2000
Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndromeP N Lara, T L Coe, H Zhou, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2001
Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridizationH L Liu, R Gandour-Edwards, P N Lara, et al.
Prostate Cancer and Prostatic Diseases|May 2, 2007
Inhibition of Akt pathways in the treatment of prostate cancerE C Nelson, C P Evans, P C Mack, et al.
Prostate Cancer and Prostatic Diseases|November 1, 2006
Clinical implications of neuroendocrine differentiation in prostate cancerE C Nelson, A J Cambio, J C Yang, et al.
Prostate Cancer and Prostatic Diseases|February 11, 2015
Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patientsE N Lo, L A Beckett, C X Pan, et al.
Investigational New Drugs|July 30, 1999
Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124)F J Meyers, D Lew, P N Lara, et al.
Oncogene|March 26, 2014
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft modelH G Nguyen, J C Yang, H-J Kung, et al.
Cancer Chemotherapy and Pharmacology|October 27, 1998
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinicallyP N Lara, D R Gandara, G T Wurz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Lung Cancer (Amsterdam, Netherlands)|December 13, 2001
Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approachD R Gandara, P N Lara, D H Lau, et al.
The American Journal of Medicine|January 7, 2000
Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndromeP N Lara, T L Coe, H Zhou, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2001
Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridizationH L Liu, R Gandour-Edwards, P N Lara, et al.
Prostate Cancer and Prostatic Diseases|May 2, 2007
Inhibition of Akt pathways in the treatment of prostate cancerE C Nelson, C P Evans, P C Mack, et al.
Prostate Cancer and Prostatic Diseases|November 1, 2006
Clinical implications of neuroendocrine differentiation in prostate cancerE C Nelson, A J Cambio, J C Yang, et al.
Prostate Cancer and Prostatic Diseases|February 11, 2015
Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patientsE N Lo, L A Beckett, C X Pan, et al.
Investigational New Drugs|July 30, 1999
Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124)F J Meyers, D Lew, P N Lara, et al.
Oncogene|March 26, 2014
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft modelH G Nguyen, J C Yang, H-J Kung, et al.
Cancer Chemotherapy and Pharmacology|October 27, 1998
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinicallyP N Lara, D R Gandara, G T Wurz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
Pageof 3